Navigation Links
Diamyd Gets Authorization to Begin Phase III Study in the US
Date:3/14/2008

STOCKHOLM, March 14 /PRNewswire-FirstCall/ -- Diamyd Medical AB (http://www.omxgroup.com, ticker: DIAM B; http://www.otcqx.com, ticker DMYDY). The FDA has given Diamyd Medical permission to start a Phase III clinical study in type 1 diabetes patients in the US with the therapeutic diabetes vaccine Diamyd(R).

(Logo: http://www.newscom.com/cgi-bin/prnh/20080314/297194 )

"We are eager to start this study and to be able to offer this promising drug to our newly diagnosed type 1 diabetes patients", says Professor Jerry Palmer, University of Washington in Seattle, USA, who will be the Lead Investigator for the US study.

"We are extremely pleased with this progress," says Elisabeth Lindner, President and CEO of Diamyd Medical. "Over the past months we have received dozens of patient inquiries with requests to participate in our Phase III type 1 diabetes studies in the US and in Europe. It is very satisfying to be able to start the studies now."

The US Phase III study will enroll 306 new-onset type 1 diabetes patients, who are within 3 months of diagnosis. Results of the study will be analyzed 15 months after all patients have been enrolled. A parallel Phase III study is planned to be conducted in Europe and together, pending a positive outcome of the trials, these pivotal studies can be used for market registration of the drug.

In a previous Phase II study in young type 1 diabetes patients, Diamyd(R) showed efficacy in preserving the patients' own insulin producing capacity for at least 30 months. No safety concerns have to date been reported in any clinical study with Diamyd(R).

Company website: http://www.diamyd.com

Diamyd Medical AB (publ). Linnegatan 89 B, SE-115 23 Stockholm, Sweden '/>"/>

SOURCE Diamyd Medical AB (publ)
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
2. Techne Corporation Announces Share Repurchase Authorization
3. Cell Therapeutics, Inc. (CTI) to Submit Marketing Authorization Application for XYOTAX(TM) for First-line Non-small Cell Lung Cancer Ahead of Schedule
4. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
5. Cell Therapeutics, Inc. Announces Authorization to Publish Italian Listing Prospectus
6. EMEA Accepts for Review Vidaza(R) Marketing Authorization Application for Higher-Risk Myelodysplastic Syndromes
7. ZARS Pharma Announces Marketing Authorization of Rapydan(R) in Europe
8. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
9. DOV Pharmaceutical, Inc. Begins Trading on OTC Bulletin Board
10. Genzyme Begins Major Expansion of Boston Manufacturing Facility
11. CalbaTech Issues Update; Beginning Training for Adult Stem Cell Collections in Atlanta
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... 2015 W. R. Grace & ... in Worms, Germany has received good manufacturing practice ... the International Pharmaceutical Excipient Council (IPEC) Foundation. ... its SYLOID® FP brand of pharmaceutical grade excipient ... the Curtis Bay, Maryland (USA) and Sorocaba, Brazil ...
(Date:5/21/2015)... As part of its philanthropic partnership with Banner ... funded a $3.25 million project to relocate and equip ... up-to-date features and technology. , The new pharmacy is ... members will begin moving from the current location to ... , The current pharmacy has been using a ...
(Date:5/21/2015)... (PRWEB) May 21, 2015 Veolia’s ... an exclusive North American distribution agreement with VWR ... system. , With more than 160 years of ... and services for laboratory and production facilities, has ... excellence and differentiated services to enable science. ...
(Date:5/20/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/x4b7kw/top_technologies ... Technologies in HW_Technical Insights" report to their offering. ... technology trends in the Health and Wellness sector and ... have an impact in the year 2015. The research ... 10 health and wellness technologies that are anticipated to ...
Breaking Biology Technology:Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 2Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 3Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2Top Technologies in the Health and Wellness Industry 2015 2
... VIEW, Calif., Jan. 26 Based on its ... & Sullivan recognizes ESBATech with the 2009 North ... Year Award for its work in developing antibody ... antibody fragment therapeutics addresses and overcomes many of ...
... (OTC Bulletin Board: PDAE) today announced that its Hereford ... under Chapter 11 of the United States Bankruptcy Code ... District of Texas. The company intends to sell its ... Section 363 sale process approved by the bankruptcy court. ...
... JOLLA, Calif., Jan. 23 Cordex Pharma, Inc., formerly known ... that it will host a scientific briefing on Thursday, January ... The keynote speaker will be Jonathan S. Stamler, MD, the ... a Professor of Medicine and of Biochemistry at Duke ...
Cached Biology Technology:Frost & Sullivan Recognizes ESBATech's Innovation in Developing Antibody Fragments for Biologic Therapeutics 2Frost & Sullivan Recognizes ESBATech's Innovation in Developing Antibody Fragments for Biologic Therapeutics 3Frost & Sullivan Recognizes ESBATech's Innovation in Developing Antibody Fragments for Biologic Therapeutics 4Panda Ethanol's Hereford, Texas Subsidiary Files Voluntary Chapter 11 2Panda Ethanol's Hereford, Texas Subsidiary Files Voluntary Chapter 11 3Cordex Pharma Presents 'New Frontiers in Cardiovascular Medicines' on January 29 2Cordex Pharma Presents 'New Frontiers in Cardiovascular Medicines' on January 29 3Cordex Pharma Presents 'New Frontiers in Cardiovascular Medicines' on January 29 4Cordex Pharma Presents 'New Frontiers in Cardiovascular Medicines' on January 29 5
(Date:5/20/2015)... DUBLIN , May 20, 2015 ... Markets ( http://www.researchandmarkets.com/research/h8t4x6/5year ) has announced the ... of the Global Iris Recognition Market" ... http://photos.prnewswire.com/prnh/20130307/600769) , ,This research service analyses ... across the government and commercial sectors, ...
(Date:5/18/2015)... Fingerprint Cards (FPC) has received an ... and FPC1035 from one if its module partners. Deliveries are ... 2015 and the sensors will be used by smartphone manufacturers ... 2015 hereby amount to 740 MSEK to date. In addition ... and a number of smaller orders not separately communicated amounting ...
(Date:5/11/2015)... N.Y. , May 11, 2015 Curemark ... announced the start of a new Phase III double ... of its novel formulation, CM-AT, on all children ages ... of its FDA Phase III double blinded clinical trial ... had low levels of the digestive enzyme chymotrypsin. This ...
Breaking Biology News(10 mins):Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... PITTSBURGHCarnegie Mellon University researchers have found that within ... neurons that behave much like people in social networks. ... of highly active members who give and receive more ... Barth, associate professor of biological sciences at Carnegie Mellon ...
... 10, 2011 Cleveland Researchers have discovered a ... undergo testing for genetic mutations of the tumor suppressor ... including several types of cancers. The research has created ... Led by Charis Eng, M.D., Ph.D., Chair of ...
... (January 9, 2011) - While age-related vision loss of ... million patients today to 55 million by the year 2050, ... vision even restored using molecular medicine. ... at the 10th annual meeting and International Conference on Recent ...
Cached Biology News:Carnegie Mellon researchers identify 'Facebook neurons' 2Carnegie Mellon researchers identify 'Facebook neurons' 3Researchers create 'scoring system' for PTEN mutation testing 2Molecular medicine could avert predicted catastrophic vision loss in the aged 2Molecular medicine could avert predicted catastrophic vision loss in the aged 3
Viral CMV UL146/vCXC1 Biotinylated Affinity Purified PAb...
Request Info...
D-biotin *50 mM aqueous solution* Secondary Detection Biotin–Avidin Detection Reagents Other...
... strains are high-performance BL21 ... protein yield in T7 ... 1). Because the T7 ... more rapidly than E. ...
Biology Products: